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Abstract 
For the first time, an enzyme-based electrochemical biosensor system for determination of 
trimethylamine N-oxide (TMAO) is described. It employs an active chimeric variant of TorA 
in combination with an enzymatically deoxygenating system and a low potential mediator for 
effective regeneration of the enzyme and cathodic current generation.TMAO reductase 
(TorA) is a molybdoenzyme found in marine and most enterobacteria that catalyzes 
specifically the reduction of TMAO to trimethylamine (TMA). The chimeric TorA named 
TorA-FDH corresponds to the apoform of TorA from Escherichia coli reconstituted with the 
molybdenum cofactor from formate dehydrogenase (FDH). Each enzyme, TorA and TorA-
FDH, was immobilized on the surface of a carbon electrode and covered with a dialysis 
membrane. The biosensor operates at an applied potential of -0.8 V (vs. Ag/AgCl (1M KCl)) 
under ambient air conditions thanks to an additional enzymatic O2-scavenger system. A 
comparison between the two enzymes revealed a much higher sensitivity for the biosensor 
with immobilized TorA-FDH. The biosensor exhibits a sensitivity of 14.16 nA/µM TMAO in 
a useful measuring range of 2 -110 µM with a detection limit of LOD = 2.96 nM (n = 3), 
almost similar for TMAO in buffer and in spiked serum samples. With a response time of 16 
± 2 s the biosensor is stable over prolonged daily measurements (n=20). This electrochemical 
biosensor provides suitable applications in detecting TMAO levels in human serum. 
 
Keywords: Trimethylamine N-oxide (TMAO), TMAO reductase, chimeric enzyme, 
molybdoenzyme, electrochemical biosensor 
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1. Introduction 
 
Trimethylamine N-oxide (TMAO) is an organic end-product originating from the degradation 
of dietary trimethylamine containing compounds like choline, carnitine and lecithin 
(Velasquez et al., 2016). After ingestion of food rich in these compounds the gut microbiota 
degrades them to trimethylamine (TMA), which is further transferred to the liver where the 
flavin dependent monooxygenase (FMO) family of enzymes converts it to TMAO. This 
TMAO is mostly excreted through urine (Fennema et al., 2016). In recent years this molecule 
has emerged as a potential biomarker for several disease states. Clinical reports have pointed 
to the involvement of TMAO in the development of atherosclerosis (Bennett et al., 2013) and 
its correlation to the development and progression of cardiovascular diseases (Wang et al., 
2011). A link between high levels of TMAO in the plasma and the increased risk of 
developing colorectal cancer among postmenopausal women was also found (Bae et al., 
2014). Given the main clearance of TMAO from the body is through urine (Smith et al., 
1994), increased negative effects have also been reported in patients with chronic kidney 
disease (Bell et al., 1991; Stubbs et al., 2016).  
Even though the emerging importance of the TMAO as a biomarker has been recognized 
there is yet no specific method for the detection of this molecule that could be used quickly 
outside the laboratory. Most of the reported methods in literature are analytical approaches 
that first need the reduction of TMAO to TMA (daCosta et al., 1990) or some other 
preparation methods that involve organic toxic solvents and labeling. In some cases, an 
additional derivatization of the TMA is also needed in order to get an estimate of the TMAO 
levels. Methods like ion or liquid chromatography and nuclear magnetic resonance (NMR) 
were mostly used in the developed procedures for determining the TMAO levels (Bell et al., 
1991; Mamer et al., 2010; Wang et al., 2014). Apart from the reported unspecific microbial 
biosensor (Gamati et al., 1991) a specific electrochemical biosensor approach, to our 
knowledge, is not yet developed.  
Most of the biosensors available on the market are based on oxidases and operate at positive 
potentials. In contrast, the use of reductase reactions usually requires potentials where 
dissolved oxygen interferes and therefore, it has to be removed beforehand. The combination 
of glucose oxidase and catalase is well established for deoxygenation of solutions for various 
analytical approaches (Benesch and Benesch, 1953; Cheng et al., 2003; Englander et al., 
1987). This approach was elaborated in great detail by Plumeré et al. for oxygen tolerant 
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biosensing of nitrate (Plumeré et al., 2012). Previously, an amperometric DMSO biosensor on 
the basis of DMSO reductase, a highly homologous enzyme to TMAO reductase was reported 
where application of glucose oxidase and catalase enabled measurements of DMSO in 
ambient air conditions (Abo et al., 2003).  
Trimethylamine N-oxide reductase, TorA, from Escherichia coli is a mononuclear 
molybdenum containing enzyme which specifically catalyzes the reduction of TMAO to 
TMA in the reaction (Buc et al., 1999): 
TMAO + 2H
+
 + 2e
-
  TMA + H2O 
It can also catalyze other N-oxide compounds, like 4-methyl morpholine N-oxide as an 
example of another prominent substrates (Iobbi-Nivol et al., 1996). Among the reported 
substrates, TMAO and morpholine N-oxide have the highest affinity for TMAO reductase and 
are catalyzed also with the highest efficiency. Recently, Kaufmann et al. reported the 
reconstitution of an active TMAO reductase from the apoform of the enzyme (apo-TorA) with 
the cofactor from Rhodobacter capsulatus formate dehydrogenase (FDH). Direct and 
mediated electrochemistry established that high electrocatalytic activities were achieved when 
the enzyme was either expressed and purified under anaerobic conditions (referred to as 
TorA-WT) or reconstituted with the FDH cofactor ligating a terminal sulfido ligand at the 
molybdenum atom (referred to as TorA-FDH) (Kaufmann et al., 2018).  
Here, we report the first electrochemical TMAO biosensor. The sensor is based on TMAO 
reduction by immobilized TorA-FDH in combination with an enzymatically deoxygenation 
system and a low potential mediator for effective regeneration of the engineered enzyme. All 
of the measurements were performed with the chimeric enzyme TorA-FDH
 
that is exhibiting 
high catalytic activity. A comparison between TorA-FDH or TorA-WT biosensor 
demonstrates that TorA-WT is less efficient than the chimeric enzyme TorA-FDH.  Given the 
higher signals obtained with mediated electrochemistry compared to direct electrochemistry, 
we chose the first one for the development of the TMAO biosensor. The glucose 
oxidase/catalase system ensured an O2 insensitive detection of TMAO by the biosensor at 
ambient air condition.  
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2. Experimental 
 
2.1. Chemicals 
Didodecyldimethylammonium bromide (DDAB) (98%), trimethylamine N-oxide dihydrate 
and methyl viologen (MV) were all purchased from Sigma-Aldrich. 
Tris(hydroxymethyl)aminomethane (TRIS) from Duchefa Biochemie B.V., 
potassiumhydrogenphosphate and glucose were purchased from Merck. Seronorm 
TM
 Human 
was from SERO AS, Norway and the cellulose membrane (MWCO 9kDa) was obtained from 
BST Biosensor Technology, Berlin. Glucose oxidase (GOx) (Type II ≥ 15000 U/g) and 
Catalase (Cat, from bovine liver) (2000-5000 U/mg) were purchased from Sigma. The two 
TMAO reductases used are TorA-FDH (228 U/mg; kcat 360 s
-1
) and TorA-WT (593 U/mg; kcat 
934 s
-1
). All the other used reagents were of lab grade purity and used without further 
purification.  
2.2. Apparatus and procedures 
The electrochemical experiments were carried out in a lab-made three-electrode cell with a 
total volume of 1 mL, employing a platinum wire as counter electrode, an Ag/AgCl (1 M 
KCl) reference electrode (Microelectrodes Inc., Bedford, USA) against which all potentials 
are reported. Cyclic voltammetry (CV) was performed with a modified graphite rod working 
electrode (Alfa Aesar, Karlsruhe, Germany). A glassy carbon electrode (BAS) was employed 
as the working electrode in all amperometric measurements for the development of the 
biosensor. All electrochemical experiments were performed at room temperature using 
PalmSens potentiostat and analyzed with PSLite 4.8 software (Palmsens, The Netherlands) 
and OriginPro 2017. The CV experiments were performed in a glovebox (COY, USA) at 
room temperature and under anaerobic conditions (minimum of 2% H2 and 98% N2).  
In CV, the potential on the working electrode was cycled between -0.2 V and -0.8 V for the 
direct bioelectrocatalysis and between -0.3 V and -0.9 V for the mediated bioelectrocatalysis, 
all at 5 mV/s scan rate and stirred solution. In amperometry, the potential applied on the 
working electrode was held at constant value of -0.8 V.  
The biosensor characterization was performed under ambient air conditions using 8 U GOx 
and 200 U Cat of final activity together with 50 mM glucose to insure O2 removal from the 
measuring cell. A lid on top of the cell was placed to limit the O2 dissolving into the 
measuring buffer during the measurement.  
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2.3. Electrode modification  
2.3.1. CV measurements 
 Prior to modification the graphite rod electrode with diameter of 3.5 mm was cleaned by 
polishing with emery paper with two different grit sizes (200 and 1500) and then 
ultrasonicated in Milli-Q water for 20 s and dried under N2 stream. The electrode modification 
was carried out based on a published procedure (Aguey-Zinsou et al., 2002). Briefly the 
cleaned electrode was modified with a mixture of 1:1 volume ratio of 2 mM DDAB and 265 
µM TorA-FDH. A 6 µL of this mixture was drop casted onto the electrode surface and left to 
dry in a desiccator at 4 °C for 15-20 min. The modified electrode was then transferred into the 
anaerobic glovebox and used for the voltammetric experiments. The same procedure was 
applied for the mediated and direct electrochemistry.  
2.3.2. Biosensor 
A glassy carbon electrode was cleaned with two different grain size Al2O3, 1 µm and 0.3 µm 
respectively, then ultrasonicated in Milli-Q water for 10 min, washed thoroughly and dried 
under N2 stream. The electrode modification was performed by drop casting 5 µL of enzyme 
(TorA-FDH or TorA-WT) and drying in a desiccator at 4 °C for 30 min. Afterwards the 
electrode was covered with a dialysis membrane and fastened in the cell with an O-ring 
assembly. All biosensor measurements were performed under standard lab condition in air 
and at room temperature.  
2.4. Protein purification and reconstitution 
The purification of E. coli TorA, apo-TorA and the reconstitution of apo-TorA with the 
cofactor of R. capsulatus formate dehydrogenase were performed as described in Kaufmann 
et al. (Kaufmann et al., 2018). 
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3. Results and discussion  
3.1. Direct versus mediated bioelectrocatalysis  
In a recent study, we reported on the direct electrocatalytic reaction of TorA and the in vitro 
reconstituted chimera of this enzyme in order to indicate the role of the first coordination 
sphere of the cofactor on its potential and its activity (Kaufmann et al., 2018). TorA-FDH was 
among the most active enzyme variants. Fig 1A is depicting the CV of the direct 
bioelectrocatalysis of TMAO by the immobilized TorA-FDH. After addition of 3 mM TMAO 
as substrate (black trace) a clear evolution of a biocatalytic reduction current can be seen. 
From the first derivative of the reduction part of the bioelectrocatalytic curve the catalytic 
potential Ecat = -0.56 V is determined (SI Fig 1). The catalytic potential (Ecat) is described as 
the maximum of the first derivative (dI/dE) or the inflection point  where the 
bioelectrocatalytic current plateaus on both sides (Fourmond et al., 2013). This potential 
should be close to the redox potential of the center where catalysis takes place or/and to the 
redox potential of the center which is a limiting factor during the electron transfer event (Zu et 
al., 2003). Given that TMAO reductase carries only the redox center bis-MGD, we can 
ascribe the measured catalytic potential to represent a close value of the potential of the redox 
active center. Then, a similar experiment was conducted except that a mediator was added 
(Fig 1B). Methyl viologen was selected mostly because of its negative redox potential (E° = -
0.446 V vs. NHE (i.e., = -0.645 V vs. Ag/AgCl (1 M KCl)) (Michaelis and Hill, 1933). As 
shown in Fig 1b, the addition of TMAO in the presence of methyl viologen leads to a strong 
current increase. Indeed, the bioelectrocatalytic current is more than 80 times higher than in 
the unmediated bioelectrocatalysis.  The efficiency of the electron transfer is obviously much 
higher in the presence of mediator. In mediated electrochemistry, the molecules which are not 
in direct contact with the electrode also contribute to the total biocatalytic current output. This 
makes the use of a mediator a much more desirable approach for the construction of 
biosensors where small concentrations of substrates should be detected.  
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Figure 1. A) Direct and B) mediated bioelectrocatalysis of TMAO by immobilized TorA-FDH. CV of 
the immobilized TorA-FDH electrode before (grey trace) and after (black trace) addition of 3 mM 
TMAO, recorded A) without and B) in the presence of 1 mM methyl viologen. Please note the 
different current ranges. Other conditions: Anaerobic, potassium phosphate buffer 10 mM pH 6.5; 
scan rate: 5 mV/s. 
 
3.2. Biosensor 
The previous voltammetric experiments were conducted in a glovebox in order to prevent the 
interferences coming from oxygen. The biosensor is intended to be applicable under standard, 
environmental conditions (in ambient air) in the lab. Therefore, the buffer solution was 
enzymatically deoxygenated during the measurements and glassy carbon was used instead of 
graphite. Graphite is very porous and could not completely be deoxygenated. TorA-FDH was 
immobilized onto a glassy carbon electrode by adsorption and trapped under a permselective 
membrane. The biosensor was evaluated using amperometry. When the electrode is polarized 
at – 0.8 V a rapid evolution of a catalytic reduction current is seen after TMAO addition to a 
buffer containing MV as soluble mediator (Fig. 2). Fig. 2 shows the typical steady state 
response curve and the schematic of the reaction sequence of the biosensor. A small peak 
appears immediately after the injection of TMAO, which vanishes within seconds and can be 
explained by disturbances from the sample injection, while a large stationary reduction 
current evolves. TMAO is reduced to TMA with concomitant oxidation of the enzyme. The 
reducing equivalents are delivered by MV
+●
, which is regenerated at the electrode. As a result, 
a catalytic current is generated proportional to TMAO concentration. No significant reduction 
current appeared when the enzyme was not immobilized on the electrode surface.  
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Figure 2. Amperometric curve of mediated reduction of 100 µM TMAO by immobilized TorA-FDH 
(left). On the right is a scheme representing the immobilized enzyme and the reaction with TMAO and 
the recycling of methyl viologen on the electrode surface. Potassium phosphate buffer 100 mM pH 
6.5; Eappl -0.8 V; 8 U GOx, 200 U Cat and 50 mM glucose; 250 µM methyl viologen 
 
Methyl viologen is a suitable mediator. In order to determine the optimum conditions for the 
biosensor the concentration of MV was varied between 50 nM and 1 mM and the sensor 
response for 100 µM TMAO was evaluated. Even very low concentrations of mediator gave a 
response after addition of substrate. As can be seen on SI Fig 2. the enzyme has a high affinity 
for the mediator (  = 0.36±0.1 µM). The published Km for methyl viologen is 150 µM 
(Nihon Seikagakkai. et al., 1986). The lower value here is due to the cyclic regeneration of the 
mediator on the electrode surface. The current reached a saturation value at 250 µM, above 
which no further current increase was measurable. This was reminiscent of what was 
observed for the DMSO biosensor. Indeed, Abo et al. reported low concentrations of MV, (5 
or 50 µМ) depending on the needed sensitivity for the detection of DMSO (Abo et al., 2003).  
To guarantee no mediator limitation for all further measurements of TMAO, we used 250 µM 
of MV. 
The amount of enzyme used for immobilization was additionally varied. Increase of the 
enzyme amount (and thus the enzyme activity) led to a growth of sensor sensitivity until a 
maximum indicating that the sensor response changed from kinetic to diffusion limitation. 
Fig. 3 represents the results of the loading test. Remarkably, the maximum response for 
TMAO is already reached at very low amount of TorA-FDH (7,07 pmol/cm
2
) (Fig. 3). Due to 
the higher enzymatic activity of TorA-FDH, its loading is much lower compared to other 
described enzyme electrodes in which an enzyme is adsorbed on electrode surfaces (Schulz et 
al., 2014; Tavahodi et al., 2017). However, a tenfold reduction of the applied amount resulted 
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in a clear drop of response. In order to have sufficient excess of enzyme and the highest 
response for further studies, we applied 5.9 nmol/cm
2
. Enzyme excess typically secures 
stability and longer measuring range.  
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Figure 3. Enzyme loading dependence. Graph of the measured amperometric current versus the 
electrode applied TorA-FDH concentration. Potassium phosphate buffer 100 mM pH 6.5; TMAO 100 
µM; Methyl viologen 250 µM; GOx 8 U, Cat 200 U and glucose 50 mM.  (n=3 electrodes) 
  
3.3. Comparison between TorA-FDH and TorA-WT  
In our previous work, we showed that the current increase at 3 mM TMAO in the presence of 
1 mM MV was nearly the same for TorA-FDH and TorA-WT (81.99±8.53 and 83.16±3.5 µA, 
respectively), indicating that TorA-FDH and TorA-WT are comparably active (Kaufmann et 
al., 2018). Here, we compared the response of the immobilized TorA-WT and TorA-FDH 
under the newly defined conditions. From Fig. 4, it is obvious that now the enzyme response 
is not similar. In the presence of 100 µM of TMAO, TorA-WT is less efficient than TorA-
FDH (323±81 nA vs. 440±26 nA, respectively). The current response for the TorA WT-
modified electrode for 2 µM TMAO is also visibly decreased to 19.3±15 nA, which is almost 
half of that of the TorA-FDH modified electrode (28.3±1 nA).  
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Figure 4. Comparison between the activity of TorA-FDH and TorA-WT.  Potassium phosphate buffer 
100 mM pH 6.5; TMAO 100 µM; Methyl viologen 250 µM; GOx 8 U, Cat 200 U and glucose 50 mM; 
Eappl -0.8 V (n=3 electrodes). 
 
Furthermore, the response of the TorA WT sensor is less reproducible between sensor 
preparations. The larger variation between the sensors can be explained by differences in the 
sensitivity to oxygen since the TorA WT was expressed and purified under anaerobic 
conditions. It was already reported that a contact of the WT enzyme with oxygen can damage 
the cofactor and as a result lower the activity of the enzyme (Kaufmann et al., 2018).  
Since the TorA-FDH variant seems to be less susceptible to oxidative damage compared to 
the WT enzyme it was selected for the construction of the biosensor for TMAO detection. 
 
3.4. Biosensor performance 
 
The biosensor was thus constructed with TorA-FDH immobilized on the electrode surface 
(5.9 nmol/cm
2
) and addition of MV (250 µM). As shown by the above results, this biosensor 
can be used even in the presence of oxygen since the chimeric TorA-FDH enzyme remains 
stable. The performances of the biosensor were then tested.  
Fig 5A shows the dependence of the amperometric current on TMAO concentration. The 
useful measuring range is from 2 to 110 µM TMAO but the range of linearity is much longer 
(~10 mM TMAO) (SI Fig 3). The response time is 16±2 s and the sensitivity is 14.16 nA/µM 
TMAO with a limit of detection of LOD = 2.96 nM (S/N n = 3). The reported values of 
TMAO concentrations in the human blood plasma of a healthy person are between 2.25 – 5.79 
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µM for both man and woman (Kühn et al., 2017; Wang et al., 2014). Higher values of around 
100 µM TMAO were reported mostly for patients with chronic kidney disease but also 
associated with other disease states (Mafra et al., 2014; Stubbs et al., 2016; Zhu et al., 2016). 
As can be seen from the graph (Fig 5A) the linear range is in the total range of our interest.  
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Figure 5. Graph of the current response versus the concentration of TMAO A) N2 purging additional 
on the O2 removal system (squares) and without purging (triangles). B) in undiluted serum (triangles) 
and in buffer solution (squares). Potassium phosphate buffer 100 mM pH 6.5; Range of TMAO 2-110 
µM; Methyl viologen 250 µM; GOx 8 U, Cat 200 U and glucose 50 mM, (n=3 electrodes) 
 
To validate the oxygen removal system and confirm our results, the same measurement was 
performed except that additional N2 purging was applied before and during the measurement 
(Fig 5A, squares). Thus, the measuring buffer containing GOx, Cat and glucose was purged 
with N2 prior to the measurement for 30 min and then gently flushed continuously over the 
liquid phase during the whole measurement cycle. It is clear from the graph depicting the 
current versus the applied TMAO concentration that there is no difference in the performance 
between the sensor responses and thus, the O2 removal capacity of the system is optimal and 
no residual oxygen interferes during the measurements. 
Further, we also tested the reproducibility and stability of the biosensor. No obvious decrease 
of response was noted after 20 repetitive measurements over a period of 6 hours. The relative 
standard deviation (RSD) for these measurements is 8.8 %. Between each measurement the 
measuring cell was washed thoroughly with the measuring buffer. The results (SI Fig 4) 
indicate that the biosensor is stable for prolonged measurements during one day. After storage 
of the biosensor in 75 mM Tris buffer (currently used for enzyme storage in solution) at 4 °C 
for one week, the signal response dropped only by ≈ 13 % (12.67±4 %; SI Fig 5). Since the 
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electrode is covered with a dialysis membrane which prevents leaching of the enzyme from 
the electrode surface, we ascribe this loss of the initial response to the enzyme inactivation.   
 
3.5. Biosensor performance in serum 
 
A potential application of the biosensor is the determination of TMAO in serum samples. 
Therefore, recovery of TMAO in serum was tested and also the effect of serum on the 
sensitivity of the TMAO biosensor. An important point for the performance of this biosensor 
is the very small influence of the serum on the signal produced from the catalysis of TMAO 
by the immobilized TMAO reductase. In a series of experiments, we tested this aspect by 
injecting diluted serum spiked with 20 µM TMAO. The response was only 7 % lower for the 
spiked human serum sample compared to the same concentration of TMAO in buffer solution 
(67±0.5 nA vs. 72±1 nA, respectively) (SI Fig 6). This indicates that there are no substances 
in serum that can significantly interfere during the detection of TMAO by the immobilized 
TorA-FDH which is highly specific for TMAO.  
The next measurement was performed in undiluted serum containing additionally the O2 
removing system. After equilibration of the sensor the current generated upon consecutive 
additions of TMAO at different concentrations was evaluated. As can be seen from Fig 5b 
(black squares) the linearity and sensitivity in the range between 2-110 µM are nearly the 
same compared to measurement in pure buffer solution (red circles) where the sensitivity in 
buffer solution is 14.16 nA/µM and in undiluted serum solution 13.75 nA/µM TMAO. This 
shows that the biosensor can perform the measurements without any interferences or need for 
serum dilution for detecting the TMAO in a real time serum sample. Altogether these results 
indicate that the sensitivity is not markedly influenced when using real samples. 
 
4. Conclusion 
 
Here, we report on the development of the first enzyme-based TMAO biosensor involving a 
chimeric TMAO reductase from E.coli. Such design of recognition molecules represents a 
generic approach for new biosensors.  Our results show that the biosensor made up with the 
chimeric enzyme has better characteristics than that with the wild type enzyme. The 
sensitivity and linear range of operation of the reported biosensor is in the desirable range for 
addressing the values of TMAO in blood of healthy people. The short-term usage stability is 
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quite good. The sensor can operate over prolonged daily measurements. The serum 
measurements show that a detection of TMAO in human serum can be performed without 
interferences from the complex serum matrix. Furthermore, the incorporated O2 removal 
system, consisting of GOx and Cat allows for performing measurements under ambient air 
conditions without intervening in the detection of TMAO and even high negative potentials 
can be applied without the risk of having overlapping signals from the O2 reduction. Given 
the increased abundance of data for the involvement of TMAO in humans as a potential 
biomarker for several disease states, a fast and simple sensor for TMAO detection is 
preferred. 
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